# Iambic Therapeutics, Inc. (IAM): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Iambic Therapeutics, Inc. (IAM) is 9/100, ranked against 24,000+ stocks in 35 markets (Quality 33, Value 24, Momentum 25, each scored against its sector).

- StockRank: 9/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 33, Value 24, Momentum 25: each a 0-100 percentile within Healthcare.
- Position: #24,005 overall, #2,317 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 14.41 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 11.5M.

Source: https://moatmap.ai/stock/IAM
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker